New diabetes clinical trial: Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Published on: June 24, 2025 at 11:00PM
Conditions: Atherosclerotic Cardiovascular Disease; Overweight; Obesity
Interventions: Drug: Maridebart Cafraglutide; Drug: Placebo
Sponsors: Amgen
Not yet recruiting
https://ift.tt/rzpq2Z8